Delivery Order SPE2DB20D1100-SPE2DB25FE0TL
- Not listed
- The Defense Logistics Agency awarded a $17,908 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of HYPERRAB 300 Unit/ML vial in 5ML quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 14, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,079.06 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of September 29, 2025. This is a firm fixed-price, non-set-aside contract issued on September 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $14,053.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials (5ML) on May 30, 2025, with an ultimate completion date of June 23, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded without set-aside designation and will be...
- The Defense Logistics Agency awarded a $4,158.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of HYPERRAB 300 Unit/mL vials. This non-set-aside contract is classified as a child award under a larger contract vehicle and specifies a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 21, 2025, for the supply of HYPERRAB 300 Unit/ML Vial pharmaceutical product. This firm fixed-price delivery order carries a ceiling value of $3,465.10 with an ultimate completion date of October 10, 2025, and was awarded without set-aside designations through competitive procedures. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for HYPERRAB 300 Unit/mL Vial 5mL at a ceiling value of $10,686.55 under a firm fixed price contract. This delivery order represents a non-competitive, competitively awarded procurement with an ultimate completion date of September 24, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $42,979.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials (5 mL) with an ultimate completion date of October 17, 2025. This is a non-set-aside, competitively awarded contract with performance to be completed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with a ceiling value of $4,158.12. This is a firm fixed price delivery order with no set-aside designation, awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under a larger contract vehicle and...
- The Defense Logistics Agency awarded a $17,908 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Hyperrab 300 Unit/mL vials (5mL). This competitively awarded, non-set-aside contract reflects firm fixed pricing and is scheduled for completion by June 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for HYPERRAB 300 Unit/ml Vial pharmaceutical products with a ceiling value of $2,079.06 and a firm fixed price structure. The contract is set for ultimate completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0TLDelivery Order
The Defense Logistics Agency awarded a $21,373.10 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for HYPERRAB 300 Unit/ML Vial 5ML, with completion expected by October 14, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies. The company has demonstrated consistent capability to meet federal procurement requirements through open competition, with its DLA contract awards covering a wide spectrum of therapeutic domains including specialty medications, diabetes treatments, neurological therapies, pain management pharmaceuticals, and antibiotics. The Defense Health Agency, U.S. Coast Guard, and other government healthcare systems benefit from the flexibility and comprehensive product range provided through this prime vendor arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.4k | 9/22/25 |